dc.contributor |
Universitat de Vic - Universitat Central de Catalunya. Càtedra de la Sida i Malalties Relacionades |
|
dc.contributor.author |
Mothe, B.
|
|
dc.contributor.author |
Climent, Núria
|
|
dc.contributor.author |
Plana, Montserrat
|
|
dc.contributor.author |
Rosas, Miriam
|
|
dc.contributor.author |
Jiménez, José Luis
|
|
dc.contributor.author |
Muñoz Fernández, María Ángeles
|
|
dc.contributor.author |
Puertas, M.C.
|
|
dc.contributor.author |
Carrillo, Jorge
|
|
dc.contributor.author |
Gonzalez, Nuria
|
|
dc.contributor.author |
Leon, Agathe
|
|
dc.contributor.author |
Pich, Judit
|
|
dc.contributor.author |
Arnaiz, Joan Albert
|
|
dc.contributor.author |
Gatell, J.M.
|
|
dc.contributor.author |
Clotet, Bonaventura
|
|
dc.contributor.author |
Blanco, Julià
|
|
dc.contributor.author |
Alcamí, José
|
|
dc.contributor.author |
Martinez Picado, Francisco Javier
|
|
dc.contributor.author |
Alvarez Fernández, Carmen
|
|
dc.contributor.author |
Sánchez Palomino, Sonsoles
|
|
dc.contributor.author |
Guardo, Alberto C.
|
|
dc.contributor.author |
Peña, José
|
|
dc.contributor.author |
Benito, José M.
|
|
dc.contributor.author |
Rallón, Norma
|
|
dc.contributor.author |
Gómez, Carmen E.
|
|
dc.contributor.author |
Perdiguero, Beatriz
|
|
dc.contributor.author |
García Arriaza, Juan
|
|
dc.contributor.author |
Esteban, Mariano
|
|
dc.contributor.author |
López Bernaldo de Quirós, Juan Carlos
|
|
dc.contributor.author |
Brander, Christian
|
|
dc.contributor.author |
Garcia, Felipe
|
|
dc.date.accessioned |
2015-06-15T11:32:02Z |
|
dc.date.available |
2015-06-15T11:32:02Z |
|
dc.date.created |
2015 |
|
dc.date.issued |
2015 |
|
dc.identifier.citation |
Mothe, B., Climent, N., Plana, M., Rosàs, M., Jiménez, J. L., Muñoz-Fernández, M. A., et al. (2014). Safety and immunogenicity of a modified vaccinia ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. Journal of Antimicrobial Chemotherapy, 70(6), 1833-1842. |
ca_ES |
dc.identifier.issn |
1460-2091 |
|
dc.identifier.uri |
http://hdl.handle.net/10854/4069 |
|
dc.description.abstract |
Objectives: The safety, immunogenicity, impact on the latent reservoir and rebound of viral load after therapeutic
HIV-1 vaccination with recombinant modified vaccinia Ankara-based (MVA-B) HIV-1 vaccine expressing monomeric
gp120 and the fused Gag-Pol-Nef polyprotein of clade B with or without a drug to reactivate latent HIV-1
(disulfiram) were assessed.
Methods: HIV-1-infected patients were randomized to receive three injections of MVA-B (n¼20) or placebo
(n¼10). Twelve patients (eight who received vaccine and four who were given placebo) received a fourth dose
of MVA-B followed by 3 months of disulfiram. Combined ART (cART) was discontinued 8 weeks after the last dose
of MVA-B. Clinical Trials.gov identifier: NCT01571466.
Results: MVA-B was safe and well tolerated. A minor, but significant, increase in the T cell responses targeting vaccine
inserts of Gag was observed [a median of 290, 403 and 435 spot-forming-cells/106 PBMCs at baseline, after
two vaccinations and after three vaccinations, respectively; P¼0.02 and P¼0.04]. After interruption of cART, a
modest delay in the rebound of the plasma viral load in participants receiving vaccine but not disulfiram was
observed compared with placebo recipients (P¼0.01). The dynamics of the viral load rebound did not change in
patients receiving MVA-B/disulfiram. No changes in the proviral reservoir were observed after disulfiram treatment.
Conclusions: MVA-B vaccination was a safe strategy to increase Gag-specific T cell responses in chronically HIV-1-
infected individuals, but it did not have a major impact on the latent reservoir or the rebound of plasma viral load
after interruption of cART when given alone or in combination with disulfiram. |
ca_ES |
dc.format |
application/pdf |
|
dc.format.extent |
10 p. |
ca_ES |
dc.language.iso |
eng |
ca_ES |
dc.publisher |
Oxford University Press |
ca_ES |
dc.rights |
Tots els drets reservats |
ca_ES |
dc.rights |
(c) Oxford University Press |
|
dc.subject.other |
Sida -- Tractament |
ca_ES |
dc.subject.other |
VIH (Virus) |
ca_ES |
dc.title |
Safety and immunogenicity of a modified vaccinia ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1 |
ca_ES |
dc.type |
info:eu-repo/semantics/article |
ca_ES |
dc.identifier.doi |
https://doi.org/10.1093/jac/dkv046 |
|
dc.rights.accessRights |
info:eu-repo/semantics/closedAccess |
ca_ES |
dc.type.version |
info:eu-repo/publishedVersion |
ca_ES |
dc.indexacio |
Indexat a SCOPUS |
ca_ES |
dc.indexacio |
Indexat a WOS/JCR |
|